Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment publishing date : 2021 - 06 - 24 save search
Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
Published: 2021-06-24 (Crawled : 21:00) - biospace.com/
MGNX | $16.27 1.06% 140K
|
Health Technology
|
| O: -0.08%
H: 4.26%
C: 2.15%
INCY | $52.46 -0.49% 330K
|
Health Technology
|
| O: 0.33%
H: 1.31%
C: 0.84%
treatment fda oda drug cell carcinoma
Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks
Published: 2021-06-24 (Crawled : 14:00) - biospace.com/
GILD | $65.99 -1.4% 1.9M
|
Health Technology
|
| O: 0.18%
H: 2.2%
C: 0.61%
treatment hepatitis response
Neurent Medical Expands Leadership Team to Support Advancement of In-Office Chronic Rhinitis Treatment
Published: 2021-06-24 (Crawled : 13:00) - biospace.com/
SNN | $24.025 0.44% 240K
|
Health Technology
|
| O: 0.9%
H: 0.32%
C: -0.11%
MDT | News | $78.7 -0.48% 1.7M
|
Health Technology
|
| O: 0.1%
H: 0.15%
C: -0.41%
treatment
AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma
Published: 2021-06-24 (Crawled : 13:00) - biospace.com/
ABBV | $167.2 1.8% 1.3M
|
Health Technology
|
| O: 0.37%
H: 1.55%
C: 0.28%
treatment potential
Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer
Published: 2021-06-24 (Crawled : 12:15) - biospace.com/
PIRS | $0.163 3.76% 180K
|
Health Technology
|
| O: 5.65%
H: 22.19%
C: 16.84%
treatment cancer drug designation
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Published: 2021-06-24 (Crawled : 12:15) - globenewswire.com
CRBP M | $37.43 0.73% 23K
|
Health Technology
|
| O: -15.58%
H: 24.4%
C: 23.21%
treatment results topline phase 3
LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Published: 2021-06-24 (Crawled : 12:00) - biospace.com/
MRK | $124.9 -0.38% 1.4M
|
Health Technology
|
| O: 0.2%
H: 1.2%
C: 0.83%
treatment prostate cancer china cancer
Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
Published: 2021-06-24 (Crawled : 12:00) - biospace.com/
ALNY | $146.09 0.53% 59K
|
Health Technology
|
| O: 0.96%
H: 0.37%
C: -1.49%
new drug food treatment drug
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
Published: 2021-06-24 (Crawled : 11:00) - prnewswire.com
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 8.21%
H: 1.89%
C: -0.83%
disease alzheimer treatment fda therapy breakthrough therapy alzheimer’s alzheimer's disease alzheimer's designation
Benign Prostatic Hyperplasia Treatment Market To Be Worth ~$17 Billion by 2030 Says P&S Intelligence
Published: 2021-06-24 (Crawled : 06:00) - prnewswire.com
MDT | News | $78.7 -0.48% 1.7M
|
Health Technology
|
| O: 0.1%
H: 0.15%
C: -0.41%
BSX | $67.96 1.3M
|
Health Technology
|
| O: 0.46%
H: 0.48%
C: -0.64%
treatment
Gainers vs Losers
| 82% | 18% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8258 70.34% 50M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
VTNR S | $1.295 32.25% 5.5M
|
Industrial Services
ALRN | $5.53 30.12% 250K
|
Health Technology
SMSI 4 | $2.53 29.74% 510K
|
Technology Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.